Jorge E Cortes, MD
M.D. Anderson Cancer Center
8
7
7
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+4 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (8)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Hagop M Kantarjian, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Karen Yee, MD
Princess Margaret Hospital, Canada
Shared therapeutic areas:
Worked with same sponsors:
Harry Erba, MD
University of Michigan
Shared therapeutic areas:
Worked with same sponsors:
Steven Allen, MD
Monter Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Gerrit J Ossenkoppele, MD
VUMC
Shared therapeutic areas:
Worked with same sponsors:
Richard Larson, MD
University of Chicago
Shared therapeutic areas:
Worked with same sponsors:
Shambavi Richard, MD
Stony Brook University Medical Center
Shared therapeutic areas:
Worked with same sponsors:
Eric Feldman, MD
Weill Cornell Medical College - New York Presbyterian Hospital
Shared therapeutic areas:
Worked with same sponsors:
Aarthi Shenoy, MD
Medstar Health Research Institute
Shared therapeutic areas:
Worked with same sponsors:
Hanna J Khoury, MD
Emory University Clinic
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (8)
Showing 8 of 8 trials
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia
Therapy of Early Chronic Phase CML With Gleevec
High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)
Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML
Investigation of Clofarabine in Acute Leukemias
Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML
All 8 trials loaded